PUNE, India, October 7, 2016 /PRNewswire/ --
RnRMarketResearch.com adds "Pre-Eclampsia - Pipeline Review, H2 2016" market research report that provides an overview of the Pre-eclampsia's therapeutic pipeline with comprehensive information on the therapeutic development for Pre-Eclampsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pre-Eclampsia and special features on late-stage and discontinued projects.
Complete report on H2 2016 pipeline review of Pre-Eclampsia with 20 market data tables and 13 figures, spread across 63 pages is available at http://www.rnrmarketresearch.com/pre-eclampsia-pipeline-review-h2-2016-market-report.html .
re-Eclampsia Pre-eclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system, often the kidneys. Signs and symptoms include severe headaches, decreased urine output, nausea or vomiting, shortness of breath, caused by fluid in lungs, impaired liver function, upper abdominal pain, usually under your ribs on the right side.
The report 'Pre-Eclampsia - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Pre-Eclampsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews of key players involved in therapeutic development for Pre-Eclampsia and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Companies discussed in this Pre-Eclampsia Pipeline Review, H2 2016 report include A1M Pharma AB, Alnylam Pharmaceuticals, Inc., Glenveigh Medical, LLC, LFB S.A., Pluristem Therapeutics Inc. and VG Life Sciences, Inc. Drug Profiles mentioned in this research report are A1M-001, ALN-AGT, antithrombin (recombinant), digoxin immune fab, PLX-PAD, RMC-035, Small Molecules to Agonize Apelin Receptor for Pre-Eclampsia and VG-1177.
Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=708039 .
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Pre-Eclampsia and reviews pipeline therapeutics for Pre-Eclampsia by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Pre-Eclampsia therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Pre-Eclampsia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Pre-Eclampsia.
Another newly published market research report titled on Polycystic Ovarian Syndrome - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Addex Therapeutics Ltd, Crinetics Pharmaceuticals, Inc., EffRx Pharmaceuticals S.A., Euroscreen S.A., Merck KGaA, Millendo Therapeutics, Inc. and Vicore Pharma AB. Polycystic Ovarian Syndrome Pipeline market research report of 55 pages is available at http://www.rnrmarketresearch.com/polycystic-ovarian-syndrome-pipeline-review-h2-2016-market-report.html .
Explore more reports on Women's Health therapeutics .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers.
2nd floor, Metropole,
Next to Inox theatre, Bund garden road,
+1 888 391 5441
SOURCE RnR Market Research